According to a recent LinkedIn post from Actithera, the company has added Erlend Eikeland Myrnes as Director of CMC Development in Oslo. The post indicates he will oversee strategic manufacturing and supply chain activities for Actithera’s next-generation radioligand therapies.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The company’s LinkedIn post highlights Myrnes’ technical background in radiopharmaceutical development and his role within the Oslo R&D hub. For investors, this suggests Actithera is strengthening its chemistry, manufacturing and controls capabilities to support tumor-focused programs as they move toward clinical supply.
The post further implies that Actithera is investing in internal expertise to advance precision molecular design in oncology. This hiring move may signal increasing operational readiness for future clinical development and could enhance the company’s positioning within the radiopharmaceutical and cancer care segments.